Hologic Receives Multi-Year Agreement from Consorta on Lorad Mammography and Radiographic Products

Hologic, Inc. (NASDAQ: HOLX) today announced that it has been awarded a two year Imaging contract with Consorta, Catholic Resource Partners. The contract covers the purchase and sale of Hologic's Radiographic and Lorad Mammographic product lines.

"The contractual relationship between Hologic and Consorta should be mutually rewarding and highly successful to both parties," said Jack Cumming, President of Lorad. "Lorad's position as the world's leading manufacturer of mammography systems and minimally invasive digital breast biopsy systems enhances our contract offering that also includes Hologic's family of radiographic products."

Hologic, Inc. develops, manufactures and markets proprietary x-ray and ultrasound systems. With more than 9,000 installations worldwide, the Company's QDR and ultrasound bone densitometers are used for the assessment of bone density and vertebral status to assist in the diagnosis and monitoring of metabolic bone diseases such as osteoporosis. FluoroScan Imaging Systems, Inc., a wholly owned subsidiary, manufactures and distributes state-of-the- art, low intensity, real time X-ray imaging devices which provide high resolution images at radiation levels and at a cost well below those of conventional X-ray and fluoroscopic equipment. Direct Radiography Corp., a wholly owned subsidiary, manufactures a state-of-the-art proprietary flat panel technology, DirectRay®, which can produce high quality digital radiographic images in seconds, thereby bypassing the need for X-ray film or chemicals. Lorad, a Hologic company, is a leading manufacturer of mammography systems.

Consorta was formed in 1998 through the consolidation of Catholic Materials Management Alliance and Sisters of the Sorrowful Mother-Diversified health Services. Consorta currently represents 284 acute care hospitals in the United States.

This News Release contains forward-looking information that involves risks and uncertainties, including statements about the Company's and Consorta's plans, objectives, expectations and intentions. Such statements include, without limitation, the belief that Consorta will purchase Hologic's radiographic and Lorad mammographic systems. There can be no assurance that actual results will not be materially different than those anticipated in these forward-looking statements. Other factors that could adversely affect the Company's business and prospects are described in the Company's reports and registration statements filed with the Securities and Exchange Commission. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.

SOURCE: Hologic, Inc.

Contact: Glenn P. Muir, Vice President, Finance, or Marianne Ritchie,
Manager, Investor Relations, both of Hologic, Inc., 781-999-7300